These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1563438)

  • 1. Magnetic resonance imaging of lower abdominal and pelvic lesions: assessment of oral magnetic particles as an intestinal contrast agent.
    Van Beers B; Grandin C; Jamart J; Demeure R; Jacobsen TF; Pringot J
    Eur J Radiol; 1992; 14(3):252-7. PubMed ID: 1563438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral magnetic particles in MR imaging of the abdomen and pelvis.
    Rinck PA; Smevik O; Nilsen G; Klepp O; Onsrud M; Oksendal A; Børseth A
    Radiology; 1991 Mar; 178(3):775-9. PubMed ID: 1994417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial of oral magnetic particles in MRI of abdomen and pelvis.
    MacVicar D; Jacobsen TF; Guy R; Husband JE
    Clin Radiol; 1993 Mar; 47(3):183-8. PubMed ID: 8472481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of hyoscine butylbromide in abdominal MR imaging with and without oral magnetic particles.
    Laniado M; Grönewäller E; Kopp AF; Kaminsky SF; Hamm B; Jacobsen TF; Claussen CD
    Abdom Imaging; 1997; 22(4):381-8. PubMed ID: 9157855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI of pelvic masses: efficacy of the rectal superparamagnetic contrast agent Ferumoxsil.
    Scheidler J; Heuck AF; Meier W; Reiser MF
    J Magn Reson Imaging; 1997; 7(6):1027-32. PubMed ID: 9400845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral superparamagnetic contrast agent (ferumoxsil): tolerance and efficacy in MR imaging of gynecologic diseases.
    Haldemann Heusler RC; Wight E; Marincek B
    J Magn Reson Imaging; 1995; 5(4):385-91. PubMed ID: 7549199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oral magnetic particles as an MR contrast medium for the gastrointestinal tract].
    Rinck PA; Myhr G; Smevik O; Børseth A
    Rofo; 1992 Dec; 157(6):533-8. PubMed ID: 1457787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation.
    Harisinghani MG; Saini S; Weissleder R; Hahn PF; Yantiss RK; Tempany C; Wood BJ; Mueller PR
    AJR Am J Roentgenol; 1999 May; 172(5):1347-51. PubMed ID: 10227514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR imaging of the gastrointestinal tract with i.v., gadolinium and diluted barium oral contrast media compared with unenhanced MR imaging and CT.
    Low RN; Francis IR
    AJR Am J Roentgenol; 1997 Oct; 169(4):1051-9. PubMed ID: 9308464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of and sequence choice for two oral contrast agents used during MR imaging.
    Grubnic S; Padhani AR; Revell PB; Husband JE
    AJR Am J Roentgenol; 1999 Jul; 173(1):173-8. PubMed ID: 10397122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abdominal MRI using a negative contrast agent.
    Bach-Gansmo T; Dupas B; Gayet-Delacroix M; Lambrechts M
    Br J Radiol; 1993 May; 66(785):420-5. PubMed ID: 8319063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
    Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
    Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral magnetic particles. Results from clinical phase II trials in 216 patients.
    Oksendal AN; Bach-Gansmo T; Jacobsen TF; Eide H; Andrew E
    Acta Radiol; 1993 Mar; 34(2):187-93. PubMed ID: 8452728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging.
    Hahn PF; Stark DD; Lewis JM; Saini S; Elizondo G; Weissleder R; Fretz CJ; Ferrucci JT
    Radiology; 1990 Jun; 175(3):695-700. PubMed ID: 2343116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of oral superparamagnetic contrast media in cholangiopancreatography with TSE single-shot magnetic resonance].
    Blandino A; Gaeta M; Mazziotti S; Settineri N; Pandolfo I
    Radiol Med; 1998; 96(1-2):87-91. PubMed ID: 9819624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferrimagnetic susceptibility contrast agents.
    Bach-Gansmo T
    Acta Radiol Suppl; 1993; 387():1-30. PubMed ID: 8390776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.
    Bluemke DA; Sahani D; Amendola M; Balzer T; Breuer J; Brown JJ; Casalino DD; Davis PL; Francis IR; Krinsky G; Lee FT; Lu D; Paulson EK; Schwartz LH; Siegelman ES; Small WC; Weber TM; Welber A; Shamsi K
    Radiology; 2005 Oct; 237(1):89-98. PubMed ID: 16126918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of barium as a gastrointestinal contrast agent in MR imaging: a comparison study in normal volunteers.
    Ros PR; Steinman RM; Torres GM; Burton SS; Panaccione JL; Rappaport DC; McGorray SP
    AJR Am J Roentgenol; 1991 Oct; 157(4):761-7. PubMed ID: 1892032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral contrast media for the magnetic resonance tomography of the abdomen. A clinical trial of the tolerance for gadolinium-DTPA].
    Kaminsky S; Laniado M; Gogoll M; Kornmesser W; Clauss W; Felix R
    Rofo; 1992 Jan; 156(1):17-23. PubMed ID: 1733470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR enteroclysis using iron oxide particles (ferristene) as an endoluminal contrast agent: an open phase III trial.
    Boraschi P; Braccini G; Gigoni R; Cartei F; Perri G
    Magn Reson Imaging; 2004 Oct; 22(8):1085-95. PubMed ID: 15527995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.